AbbVie Inc. (ABBV)
PR NewswireNov 20, '18
AbbVie to Highlight Breadth of Innovative Science and Ongoing Commitment to Blood Cancer Patients with New Data From Studies of Ibrutinib and Venetoclax at 2018 American Society of Hematology Annual Meeting & Exposition
NORTH CHICAGO, Ill. , Nov. 20, 2018 /PRNewswire/ --AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that data from nearly 40 abstracts, including 13 oral presentations and more than 20 poster presentations, will be presented during the upcoming…
SeekingAlphaNov 20, '18
Dividend Sensei's Portfolio Update 60: 2 Amazing Investing Opportunities I Bought This Week
(Source: imgflip ) Note that due to reader requests, I've decided to break up my weekly portfolio updates into three parts: commentary, economic update, and portfolio summary, stats, and watch lists. This is to avoid excessively long articles and maximize the utility to my readers. …
Finstead BitesMay 02, '18
Gilead (GILD): why this stock is undervalued
Gilead stock looks slightly undervalued at this point because the market is undervaluing Gilead’s HIV and oncology portfolios. What is the potential for this stock?
Finstead BitesMar 22, '18
AbbVie (ABBV): Will The Stock Recover?
ABBV diverted the Rova-T program today—and that led to its stock price fall by 13%. When will the stock bounce back?